Overview

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to build a data repository that can be used to understand pharmaceutical utilization patterns among patients being treated in community behavioral health organizations (CBHOs) for schizophrenia or bipolar I disorder.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Janssen Scientific Affairs, LLC
Treatments:
Antipsychotic Agents
Paliperidone Palmitate
Risperidone
Criteria
Inclusion Criteria:

- Diagnosed with schizophrenia or bipolar I disorder

- Antipsychotic use in one of the following categories: Clinician ordered initiation of
Risperidone long acting injectable in the 4 weeks prior to or on the day of enrollment
(includes patients not previously on any antipsychotic medication and those switched
from another antipsychotic)

- On continuous Risperidone long acting injectable for at least 6 months prior to
enrollment (no gaps between injections>30 days)

- Clinician ordered initiation of Paliperidone Palmitate in the 4 weeks prior to or on
the day of enrollment (includes patients not previously on any antipsychotic
medication and those switched from another antipsychotic)

- or on continuous Paliperidone Palmitate for any time period prior to enrollment

- Clinician ordered initiation of another antipsychotic in the 4 weeks prior to or on
the day of enrollment (includes patients not previously on any antipsychotic
medication and those switched from another antipsychotic)

- Not enrolled in another clinical study

- Primary source of care for schizophrenia or bipolar I disorder is the recruiting CBHO

- Agrees to all study procedures/interviews

- must sign the study informed consent document indicating that they understand the
purpose of and procedures required for the study and are willing to participate in the
study

Exclusion Criteria:

- Currently participating in a clinical study (e.g. clinical trial or observational
study) or participated in a clinical study within the past 30 days